Terns Pharmaceuticals, Inc. (TERN)

8,92 -0,18 (-1,98%) Alla chiusura: 04:00PM EDT

Terns Pharmaceuticals, Inc.

1065 East Hillsdale Boulevard
Suite 100
Foster City, CA 94404
United States
650 525 5535
https://www.ternspharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 41

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Senthil Vel Sundaram	CEO & Director	850,2k	N/D	1978
Dr. Erin Quirk M.D.	Pres & Head of R&D	662,55k	N/D	1971
Mr. Seokho Yoon Esq.	COO, Gen. Counsel & Sec.	609,37k	N/D	1978
Dr. Weidong Zhong Ph.D.	Co-Founder & Exec. Officer	N/D	N/D	1966
Dr. Mark Joseph Vignola	CFO & Treasurer	N/D	N/D	1978
Dr. Jeffrey R. Jasper Ph.D.	Sr. VP & Head of Research	N/D	N/D	N/D
Ms. Diana Chung	Sr. VP & Chief Devel. Officer	N/D	N/D	N/D
Dr. Kerry Russell M.D., Ph.D.	Chief Medical Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Governance aziendale

L'ISS Governance QualityScore di Terns Pharmaceuticals, Inc. al 1 febbraio 2023 è 8. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 8; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.